Seeking Alpha
 

Johnson & Johnson (JNJ)

- NYSE
  • Mar. 15, 2012, 10:56 AM
    Johnson & Johnson's (JNJ) William Weldon has been ripped as one of America's most-overpaid big company CEOs, and it looks like the coin will continue even on his way out the door: Weldon stands to collect pension benefits and deferred compensation valued at $143.5M after his retirement.
    | 9 Comments
  • Mar. 12, 2012, 1:15 PM
    Johnson & Johnson (JNJ +0.4%) faces pressure from the U.S. government to up its offer to settle a long-standong civil investigation probe into the marketing practices of the company over its antipsychotic treatment Risperdal, according to sources. The latest figure of $1.8B offered by the DOJ is considerably higher than the rejected $1B offer previously negotiated out by the U.S. Attorney's office in Philadelphia.
    | 1 Comment
  • Mar. 8, 2012, 9:57 AM
    More on Johnson & Johnson's (JNJ +1.3%) Zytiga success: The company expects to file for FDA approval in the second half of 2012 for the prostate cancer treatment. Shares of rival Dendreon (DNDN -16.3%) react negatively to the development, while Medivation (MDVN +9.2%) soars because it's developing a prostate cancer drug that is a close version of Zytiga.
    | 1 Comment
  • Mar. 8, 2012, 8:47 AM
    Word that a Zytiga phase 3 prostate cancer trial conducted by a unit of Johnson & Johnson (JNJ) was stopped early positive for efficacy creates a ripple effect with companies involved in developing prostate cancer drugs. Premarket movers: JNJ +0.7%, DNDN -15.1%, MDVN +4.4%.
    | Comment!
  • Feb. 29, 2012, 10:17 AM
    Morningstar's Ultimate Stock Pickers offer their 10 highest conviction buys: GILD, GSK, RIMM, C, DVN, ITW, SCHW, JNJ, TIF, DHR.
    | Comment!
  • Feb. 22, 2012, 8:48 AM
    Johnson & Johnson (JNJ) has submitted concessions in a bid to ease EU regulatory concerns over its $21.3B purchase of Swiss medical device maker Synthes, the EC says. Analysts speculate that JNJ may have to divest some trauma assets to win regulatory approval.
    | Comment!
  • Feb. 21, 2012, 4:43 PM
    Johnson & Johnson (JNJ) CEO Bill Weldon announces his retirement, following an embarrassing stretch of product recalls and speculation in winter 2010 that he would step down within the year. Alex Gorsky, head of medical devices and diagnostics, succeeds him.
    | 2 Comments
  • Feb. 21, 2012, 10:53 AM
    The Supreme Court rejects a request from Johnson & Johnson (JNJ -0.1%) to reinstate a $1.67B court ruling against Abbott Laboratories (ABT -0.4%) in a patent infringement case related to its Humira treatment for arthritis that contributes close to 20% of ABT's annual revenue.
    | Comment!
  • Feb. 17, 2012, 9:04 AM
    Johnson & Johnson (JNJ) is recalling about 574K bottles of its grape-flavored liquid infant Tylenol in the U.S. following complaints (but no adverse events) over the dosing system. It's the latest in a series of recalls involving Tylenol and other over-the-counter medications. (PR)
    | Comment!
  • Feb. 8, 2012, 1:10 PM
    The FDA issues a warning on stomach-acid medications that can increase the risk of a dangerous bacterial infection. Numerours drugs include the at-risk PPI medication with Protonix, AcipHex, and Nexium being some of the larger names. Big pharma players that produce PPIs include JNJ, MRK, PFE, AZN, and ESALY.PK.
    | Comment!
  • Feb. 7, 2012, 5:55 PM
    Want a smoother ride? Bespoke presents the 40 least volatile S&P 500 names, stocks with the smallest difference between their high and low prices over the last decade. Wal-Mart (WMT) has been the least volatile stock, with a 10-year high-low spread of just 54%. Only six other S&P 500 stocks have spreads below 100%: KMB, PGN, JNJ, SCG, KO. ED.
    | 1 Comment
  • Feb. 7, 2012, 11:14 AM
    The Obama administration plans to push for a $156M increase in funding for Alzheimer's research over the next two years after estimates for Alzheimer care in the U.S. range as high as $20T for the next 40 years with baby boomers squarely in harm's way. So far drug firms have only been able to deliver stopgap measures - instead of a cure - but big names NVS, JNJ, PFE, FRX are working on developing a market-changing home run treatment, as well as smaller-cap players such as AVXL, PRANA, AEN, NYMX, and ILNS.
    | 2 Comments
  • Feb. 2, 2012, 2:33 PM
    Intuitive Surgical (ISRG +4.1%) pops after Collins Stewart (Buy) writes the Japanese Ministry of Health has indicated it will support the reimbursement of prostatectomies performed using Intuitive's da Vinci surgical robots, beginning in April. The firm also expects Intuitive and Japanese partner Johnson & Johnson (JNJ) to pursue reimbursement for other da Vinci procedures. (previously)
    | Comment!
  • Feb. 2, 2012, 11:08 AM
    Johnson & Johnson (JNJ -0.3%) lags the general market after being downgraded to Market Perform on relative valuation at First Global. The firm says JNJ's overall performance in Q4 was a mixed bag and the company's likely to level off in its growth trajectory over the near term.
    | 2 Comments
  • Jan. 31, 2012, 3:36 AM
    Johnson & Johnson (JNJ) is replacing the two chairmen in charge of its Tylenol unit, according to an internal memo seen by the WSJ, less than a year after a series of manufacturing problems and recalls prompted the leadership revamp.
    | Comment!
  • Jan. 30, 2012, 10:46 AM
    Johnson & Johnson (JNJ -0.4%) announced late Friday that it's voluntarily recalling 2,200 tubes of Aveeno-brand baby lotion from retailers in the southeastern U.S. after a sample contained too much Staphylococci, a common type of bacteria often found on the skin. The company notes the recall is precautionary and limited to a small amount of product.
    | Comment!
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.